ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "084e8ba5-75e7-4d1b-8ea4-85a2cab2e119"}, "_deposit": {"created_by": 2, "id": "2479", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "2479"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00002479", "sets": ["9"]}, "author_link": ["11494", "11491", "11489", "11486", "11487", "11493", "11492", "11490", "11488", "11485"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-06-29", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "3214", "bibliographicPageStart": "3211", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "OncoTargets and Therapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However, the patient’s blood creatinine level increased, and her physical status worsened. Alectinib also induced exacerbation of renal dysfunction but was controlled by dose reduction of 140 mg twice daily for 2 weeks treatment and 2 weeks break were repeated, and exhibited a partial response for 16 months. Here, we describe the case in which alectinib treatment had beneficial clinical effects on ALK-positive lung adenocarcinoma, which controlled the adverse renal effects by dose reduction and drug breaks.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "OncoTargets and Therapy, 10, pp.3211-3214; 2017", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Dove press Ltd"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.2147/OTT.S136837", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2017 Shimada et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution ? Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)."}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "11786930", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Shimada, Midori"}], "nameIdentifiers": [{"nameIdentifier": "11485", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "11486", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "11487", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitazaki, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "11488", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashiguchi, Kohji"}], "nameIdentifiers": [{"nameIdentifier": "11489", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda, Takaya"}], "nameIdentifiers": [{"nameIdentifier": "11490", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "11491", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "11492", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ashizawa, Kazuto"}], "nameIdentifiers": [{"nameIdentifier": "11493", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mukae, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "11494", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "OTT_10_3211.pdf", "filesize": [{"value": "698.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 698900.0, "url": {"label": "OTT_10_3211.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/2479/files/OTT_10_3211.pdf"}, "version_id": "055cf224-3832-4fd0-b8ca-d6168875efe2"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ALK", "subitem_subject_scheme": "Other"}, {"subitem_subject": "renal dysfunction", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alectinib", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/37689", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-07-31"}, "publish_date": "2017-07-31", "publish_status": "0", "recid": "2479", "relation": {}, "relation_version_is_last": true, "title": ["Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction"], "weko_shared_id": -1}
  1. 130 病院 = University Hospital
  2. 130 学術雑誌論文 = Articles in academic journal

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction

http://hdl.handle.net/10069/37689
http://hdl.handle.net/10069/37689
f86a8efd-a0e9-421c-89d6-5ae2112bab12
名前 / ファイル ライセンス アクション
OTT_10_3211.pdf OTT_10_3211.pdf (698.9 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2017-07-31
タイトル
タイトル Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
言語
言語 eng
キーワード
主題Scheme Other
主題 lung cancer
キーワード
主題Scheme Other
主題 ALK
キーワード
主題Scheme Other
主題 renal dysfunction
キーワード
主題Scheme Other
主題 alectinib
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Shimada, Midori

× Shimada, Midori

WEKO 11485

Shimada, Midori

Search repository
Fukuda, Minoru

× Fukuda, Minoru

WEKO 11486

Fukuda, Minoru

Search repository
Fukuda, Masaaki

× Fukuda, Masaaki

WEKO 11487

Fukuda, Masaaki

Search repository
Kitazaki, Takeshi

× Kitazaki, Takeshi

WEKO 11488

Kitazaki, Takeshi

Search repository
Hashiguchi, Kohji

× Hashiguchi, Kohji

WEKO 11489

Hashiguchi, Kohji

Search repository
Ikeda, Takaya

× Ikeda, Takaya

WEKO 11490

Ikeda, Takaya

Search repository
Yamaguchi, Hiroyuki

× Yamaguchi, Hiroyuki

WEKO 11491

Yamaguchi, Hiroyuki

Search repository
Nakatomi, Katsumi

× Nakatomi, Katsumi

WEKO 11492

Nakatomi, Katsumi

Search repository
Ashizawa, Kazuto

× Ashizawa, Kazuto

WEKO 11493

Ashizawa, Kazuto

Search repository
Mukae, Hiroshi

× Mukae, Hiroshi

WEKO 11494

Mukae, Hiroshi

Search repository
抄録
内容記述タイプ Abstract
内容記述 A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However, the patient’s blood creatinine level increased, and her physical status worsened. Alectinib also induced exacerbation of renal dysfunction but was controlled by dose reduction of 140 mg twice daily for 2 weeks treatment and 2 weeks break were repeated, and exhibited a partial response for 16 months. Here, we describe the case in which alectinib treatment had beneficial clinical effects on ALK-positive lung adenocarcinoma, which controlled the adverse renal effects by dose reduction and drug breaks.
書誌情報 OncoTargets and Therapy

巻 10, p. 3211-3214, 発行日 2017-06-29
出版者
出版者 Dove press Ltd
EISSN
収録物識別子タイプ ISSN
収録物識別子 11786930
DOI
関連タイプ isIdenticalTo
識別子タイプ DOI
関連識別子 10.2147/OTT.S136837
権利
権利情報 c 2017 Shimada et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution ? Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
引用
内容記述タイプ Other
内容記述 OncoTargets and Therapy, 10, pp.3211-3214; 2017
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-16 03:46:05.050771
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3